ClinicalTrials.gg
CompletedNCT00884585Updated Nov 5, 2012Results posted

Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis

A Phase 3 interventional study of Cyclosporine Vehicle and Cyclosporine 0.010% in Atopic Conjunctivitis, sponsored by Allergan. Completed at 12 sites in 12 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2012-11-05.

Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies in Conjunctivitis, Allergic with a site in United States — 6 open to participants now, 7 under way, 2 of them phase 3. Conjunctivitis, Allergic · United States.

Enrollment
20th of 90
176 · median 94
Started
2009
with 7 others
Phase 3
34 of 95
2 open now
Registered
22nd of 95
by date
Lead sponsor
3 of 95
Allergan

Among the 95 studies in Conjunctivitis, Allergic with a site in United States, this one is the 20th largest by enrollment of the 90 interventional ones that give a count, is one of 8 that started in 2009, is one of 34 in phase 3, and was the 22nd registered.

Conjunctivitis, Allergic

211 studies on the registry are indexed under Conjunctivitis, Allergic; 19 are open to participants now.

Browse Conjunctivitis, Allergic studies →

Open to participants now

6 of the 95 studies in Conjunctivitis, Allergic with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Conjunctivitis, Allergic studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Conjunctivitis, Allergic with a site in United States, or all of them as a file.
02

Study summary

This study evaluates the efficacy and safety of Cyclosporine 0.010% eye drops in the treatment of Atopic Keratoconjunctivitis (chronic and severe inflammation of the eye). The study consists of a double-masked phase, and open-labeled phase, and an open-labeled maintenance phase. For the first 3 months of the study, patients will receive either masked Cyclosporine 0.010% eye drops or vehicle four times daily; for the next 6 months, patients may receive open-labeled Cyclosporine 0.010% eye drops four times daily. At month 9, patients who are in remission, will be re-randomized to receive either open-labeled Cyclosporine 0.010% eye drops four times daily or twice daily.

03

Conditions studied

  • Atopic Conjunctivitis
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a clinical diagnosis of Atopic Keratoconjunctivitis (chronic and severe inflammation of the eye)
  • Be on stable doses of your current AKC medications for at least 2 weeks

Exclusion criteria

Exclusion Criteria:

  • You have used contact lenses within 48 hours of Day 1 or think you may have to wear contact lenses during the study
  • You are pregnant, breastfeeding, or planning to become pregnant during the study
  • You have used a calcineurin inhibitors (e.g. topical tacrolimus or topical pimecrolimus) on or around your eyes including eyelids within 4 weeks
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
176 participants (actual)

Study arms

  • Experimental
    Cyclosporine Ophthalmic Solution (COS) followed by COS

    Cyclosporine ophthalmic solution 0.010% administered 4 times a day to the qualified eye(s) for up to 12 months; at Month 9 the dose may be adjusted to 2 times a day.

    Drug: Cyclosporine 0.010%

  • Other
    Placebo followed by COS

    Placebo (cyclosporine vehicle) administered 4 times a day to the qualified eye(s) for 3 months followed by cyclosporine ophthalmic solution 0.010% up to 9 additional months; at Month 9 the dose may be adjusted to 2 times a day.

    Drug: Cyclosporine Vehicle · Drug: Cyclosporine 0.010%

Interventions

  • DrugCyclosporine Vehicle

    Placebo (cyclosporine vehicle) administered 4 times a day to the qualified eye(s) for 3 months.

  • Cyclosporine ophthalmic solution 0.010% administered 4 times a day to the qualified eye(s) for up to 12 months; at Month 9 the dose may be adjusted to 2 times a day.

06

What researchers measure

Primary outcomes

  1. Percentage of Treatment Responders

    Treatment responders are defined as patients with a ≥ 1 grade improvement from baseline in punctate corneal staining score and a ≥ 4 grade improvement from baseline in composite symptom score in the study eye. The punctate corneal staining score is assessed on a scale of 0 to 5 (0 is ≤2 dots and 5 is \>316 dots (approximately) or ulcer/erosion). The composite symptom score is based on 5 symptoms (itching, tearing, ocular discomfort, photophobia, mucous discharge). The composite symptom score (0 to 15) is the sum of 5 symptoms (each symptom is assessed on a scale of 0=absent to 3=severe).

    Time frame: Baseline, Month 2

Secondary outcomes

  1. Percentage of Punctate Corneal Staining Responders

    Punctate corneal staining responders defined as patients achieving a punctate corneal staining score of 0 or 1 in the study eye. Punctate corneal staining is assessed on a scale of 0 to 5 where 0 is ≤2 dots, 1 is \>2 dots but ≤ 10 dots, 2 is \> 10 dots but ≤ 32 dots, 3 is \> 32 dots but ≤ 100 dots (approximately), 4 is \> 100 dots (approximately) but ≤ 316 dots (approximately), and 5 is \>316 dots (approximately) or ulcer/erosion.

    Time frame: Month 2

  2. Percentage of Patients With an Improvement in the Composite Symptom Score

    Composite symptom score improvement is defined as a 4 or more grade decrease from baseline in composite symptom score in the study eye. The composite symptom score is based on 5 symptoms (itching, tearing, ocular discomfort, photophobia, mucous discharge). Each of the 5 symptoms is assessed on a scale of 0=absent to 3=severe. The composite symptom score is the sum of all 5 individual symptom scores, where 0 is no symptoms and 15 is the most severe symptoms.

    Time frame: Baseline, Month 2

  3. Percentage of Patients With an Improvement in the Punctate Corneal Staining Score

    Punctate corneal staining improvement is defined as a 1 or more grade decrease from baseline in the study eye. The punctate corneal staining score is assessed on a scale of 0 to 5 where 0 is ≤2 dots, 1 is \>2 dots but ≤ 10 dots, 2 is \> 10 dots but ≤ 32 dots, 3 is \> 32 dots but ≤ 100 dots (approximately), 4 is \> 100 dots (approximately) but ≤ 316 dots (approximately), and 5 is \>316 dots (approximately) or ulcer/erosion.

    Time frame: Baseline, Month 2

07

Results

Posted Nov 5, 2012

Participant flow

Double-Masked Phase (Day 1-Month 3)
Participant flow — Double-Masked Phase (Day 1-Month 3)
MilestoneCyclosporine Ophthalmic Solution (COS) Followed by COSPlacebo Followed by COS
Started8987
Completed7983
Not completed104
Open-Label Phase (Months 3-9)
Participant flow — Open-Label Phase (Months 3-9)
MilestoneCyclosporine Ophthalmic Solution (COS) Followed by COSPlacebo Followed by COS
Started1620
Completed1470
Not completed150
Open-Label Maintenance (Months 9-12)
Participant flow — Open-Label Maintenance (Months 9-12)
MilestoneCyclosporine Ophthalmic Solution (COS) Followed by COSPlacebo Followed by COS
Started1470
Completed1440
Not completed30

Outcome measures

PrimaryPercentage of Treatment Responders

Treatment responders are defined as patients with a ≥ 1 grade improvement from baseline in punctate corneal staining score and a ≥ 4 grade improvement from baseline in composite symptom score in the study eye. The punctate corneal staining score is assessed on a scale of 0 to 5 (0 is ≤2 dots and 5 is \>316 dots (approximately) or ulcer/erosion). The composite symptom score is based on 5 symptoms (itching, tearing, ocular discomfort, photophobia, mucous discharge). The composite symptom score (0 to 15) is the sum of 5 symptoms (each symptom is assessed on a scale of 0=absent to 3=severe).

Time frame:
Baseline, Month 2
Reported as:
Number · Percentage of Patients
Percentage of Treatment Responders
Percentage of PatientsCyclosporine Ophthalmic Solution (COS) Followed by COSPlacebo
Percentage of Treatment Responders21.317.2
SecondaryPercentage of Punctate Corneal Staining Responders

Punctate corneal staining responders defined as patients achieving a punctate corneal staining score of 0 or 1 in the study eye. Punctate corneal staining is assessed on a scale of 0 to 5 where 0 is ≤2 dots, 1 is \>2 dots but ≤ 10 dots, 2 is \> 10 dots but ≤ 32 dots, 3 is \> 32 dots but ≤ 100 dots (approximately), 4 is \> 100 dots (approximately) but ≤ 316 dots (approximately), and 5 is \>316 dots (approximately) or ulcer/erosion.

Time frame:
Month 2
Reported as:
Number · Percentage of Patients
Percentage of Punctate Corneal Staining Responders
Percentage of PatientsCyclosporine Ophthalmic Solution (COS) Followed by COSPlacebo
Percentage of Punctate Corneal Staining Responders24.723.0
SecondaryPercentage of Patients With an Improvement in the Composite Symptom Score

Composite symptom score improvement is defined as a 4 or more grade decrease from baseline in composite symptom score in the study eye. The composite symptom score is based on 5 symptoms (itching, tearing, ocular discomfort, photophobia, mucous discharge). Each of the 5 symptoms is assessed on a scale of 0=absent to 3=severe. The composite symptom score is the sum of all 5 individual symptom scores, where 0 is no symptoms and 15 is the most severe symptoms.

Time frame:
Baseline, Month 2
Reported as:
Number · Percentage of Patients
Percentage of Patients With an Improvement in the Composite Symptom Score
Percentage of PatientsCyclosporine Ophthalmic Solution (COS) Followed by COSPlacebo
Percentage of Patients With an Improvement in the Composite Symptom Score30.328.7
SecondaryPercentage of Patients With an Improvement in the Punctate Corneal Staining Score

Punctate corneal staining improvement is defined as a 1 or more grade decrease from baseline in the study eye. The punctate corneal staining score is assessed on a scale of 0 to 5 where 0 is ≤2 dots, 1 is \>2 dots but ≤ 10 dots, 2 is \> 10 dots but ≤ 32 dots, 3 is \> 32 dots but ≤ 100 dots (approximately), 4 is \> 100 dots (approximately) but ≤ 316 dots (approximately), and 5 is \>316 dots (approximately) or ulcer/erosion.

Time frame:
Baseline, Month 2
Reported as:
Number · Percentage of Patients
Percentage of Patients With an Improvement in the Punctate Corneal Staining Score
Percentage of PatientsCyclosporine Ophthalmic Solution (COS) Followed by COSPlacebo
Percentage of Patients With an Improvement in the Punctate Corneal Staining Score42.742.5

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cyclosporine Ophthalmic Solution (COS) Followed by COS—11/171 (6.4%)44/171 (25.7%)
Placebo—3/87 (3.4%)16/87 (18.4%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventCyclosporine Ophthalmic Solution (COS) Followed by COSPlacebo
Anaphylactic ShockImmune system disorders0/1711/87
Breast CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1711/87
EpistaxisRespiratory, thoracic and mediastinal disorders0/1711/87
Forearm FractureInjury, poisoning and procedural complications1/1710/87
OsteoarthritisMusculoskeletal and connective tissue disorders1/1710/87
PneumoniaInfections and infestations1/1710/87
Infectious MononucleosisInfections and infestations1/1710/87
Prostatic Specific Antigen IncreasedInvestigations1/1710/87
Dermatitis AtopicSkin and subcutaneous tissue disorders1/1710/87
Abdominal HerniaGastrointestinal disorders1/1710/87
Most frequent other events
Most frequent other events
EventCyclosporine Ophthalmic Solution (COS) Followed by COSPlacebo
Allergic KeratitisEye disorders24/17110/87
BlepharitisEye disorders10/1713/87
Punctate KeratitisEye disorders10/1713/87

Baseline characteristics

Age, Customized
Age, Customized(Participants)Cyclosporine Ophthalmic Solution (COS) Followed by COSPlacebo Followed by COSTotal
<18 years7815
18 to <30 years151328
30 to <50 years323870
50 to <65 years272249
>=65 years8614
Sex: Female, Male
Sex: Female, Male(Participants)Cyclosporine Ophthalmic Solution (COS) Followed by COSPlacebo Followed by COSTotal
Female463985
Male434891
08

Study locations

12 sites
  • Bakersfield, California, United States
  • Randwick, New South Wales, Australia
  • Ottawa, Ontario, Canada
  • Prague, Czechia
  • Dijon, Burgundy, France
  • Munich, Bavaria, Germany
  • Bangalore, Karnataka, India
  • Tel Aviv, Israel
  • Rome, Italy
  • Wellington, New Zealand
  • Valladolid, Spain
  • Newcastle upon Tyne, Tyne and Wear, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2009, a primary completion of Oct 2010 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2012, 2 years 1 month after primary completion. A results delay was requested in Jan 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2009
First posted
Apr 21, 2009
Start
May 2009
Primary completionActual
Oct 2010
CompletionActual
Jul 2011
Results delay requested
Jan 26, 2012
Results first posted
Nov 5, 2012
Last update
Nov 5, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00884585
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Apr 21, 2009
Start date
May 2009
Primary completion
Oct 2010
Completion
Jul 2011
Results posted
Nov 5, 2012
Last update
Nov 5, 2012

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion